Literature DB >> 31006664

Clinical response and prognostic significance of serum miR-497 expression in colorectal cancer.

Guicheng Zou1,1, Rui Wang2,1, Minghui Wang3.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is a common type of cancer around the world. Detection of microRNA (miRNA) aberration in blood samples is a novel approach for CRC screening.
OBJECTIVE: The purpose of this study was to explore the serum miR-497 expression pattern in CRC and examine its potential usefulness as a biomarker for CRC diagnosis and prognosis.
METHODS: Serum miR-497 expression was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 110 patients with CRC, 35 cases with colorectal adenoma, 54 cases with colorectal polyps, and 70 healthy individuals.
RESULTS: The expression level of miR-497 was significantly downregulated in CRC tissues compared to the normal tissues based on the data from three independent studies GSE68204, GSE41655 and GSE35834. Compared to healthy controls, the serum miR-497 level was significantly decreased in patient with CRC or benign lesion (colorectal adenoma and polyps). Serum miR-497 level was dramatically increased in the post-operative blood samples from early stage CRC patients. Receiver-operating characteristic (ROC) analysis showed that serum miR-497 had a high sensitivity and specificity for discriminating CRC or precancerous colorectal lesion from normal controls. Moreover, low serum miR-497 expression was closely correlated with aggressive clinical features and shorter overall survival (OS). Kaplan-Meier analyses also revealed that OS was strongly associated with lymph node invasion, TNM stage and histological grade. Furthermore, univariate and multivariate analysis showed serum miR-497 was an independent prognostic factor for CRC.
CONCLUSIONS: Collectively, serum miR-497 may serve as a promising biomarker for diagnosis and prognosis of CRC.

Entities:  

Keywords:  Colorectal cancer; biomarker; prognosis; serum miR-497

Mesh:

Substances:

Year:  2019        PMID: 31006664     DOI: 10.3233/CBM-181902

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  8 in total

Review 1.  Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer.

Authors:  Timothy Ming-Hun Wan; Deepak Narayanan Iyer; Lui Ng
Journal:  Histol Histopathol       Date:  2019-10-16       Impact factor: 2.303

2.  High miR-3648 expression and low APC2 expression are associated with shorter survival and tumor progression in NSCLC.

Authors:  Yongquan Dong; Biao Wu; Xiongxiong Wang; Feijie Lu; Qianjun Li; Qiong Zhao
Journal:  Histol Histopathol       Date:  2021-12-20       Impact factor: 2.303

3.  IL-8, MSPa, MIF, FGF-9, ANG-2 and AgRP collection were identified for the diagnosis of colorectal cancer based on the support vector machine model.

Authors:  Mingfu Cui; Yanan Zhao; Zuocong Zhang; Yang Zhao; Songyun Han; Ruijie Wang; Dayong Ding; Xuedong Fang
Journal:  Cell Cycle       Date:  2021-03-28       Impact factor: 4.534

Review 4.  Role of cell-free network communication in alcohol-associated disorders and liver metastasis.

Authors:  Murali R Kuracha; Peter Thomas; Martin Tobi; Benita L McVicker
Journal:  World J Gastroenterol       Date:  2021-11-07       Impact factor: 5.742

5.  Association of B-cell lymphoma 2/microRNA-497 gene expression ratio score with metastasis in patients with colorectal cancer: A propensity-matched cohort analysis.

Authors:  Shahad W Kattan; Yahya H Hobani; Nouf Abubakr Babteen; Saleh A Alghamdi; Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Salwa Faisal
Journal:  J Clin Lab Anal       Date:  2022-01-07       Impact factor: 2.352

Review 6.  Colorectal liver metastasis: molecular mechanism and interventional therapy.

Authors:  Hui Zhou; Zhongtao Liu; Yongxiang Wang; Xiaoyong Wen; Eric H Amador; Liqin Yuan; Xin Ran; Li Xiong; Yuping Ran; Wei Chen; Yu Wen
Journal:  Signal Transduct Target Ther       Date:  2022-03-04

7.  Expression Levels and Clinical Significance of Serum miR-497, CEA, CA24-2, and HBsAg in Patients with Colorectal Cancer.

Authors:  Yan Liu; Jie Chen
Journal:  Biomed Res Int       Date:  2022-08-11       Impact factor: 3.246

Review 8.  Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Authors:  Aysegul Dalmizrak; Ozlem Dalmizrak
Journal:  Front Bioeng Biotechnol       Date:  2022-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.